Wake me when September ends: my reflections on the search for a treatment for Alzheimer’s disease, in honour of World Alzheimer’s month

By Dr Francesca Properzi, PhD. Research Manager, Centre for Health Solutions

Deloitte-uk-intelligent-drug-discovery

Since 2012, September has been celebrated as World Alzheimer’s Month, and this year’s theme is 'Let's talk about dementia'. This is clearly much needed, especially as one person is diagnosed with dementia every three seconds.1 As a neuroscientist, I spent more than 10 years leading a research lab dedicated to finding new approaches for diagnosing and treating neurodegenerative diseases at the Italian Institute of Health in Rome. I also had first-hand experience of the disease, as I had originally accepted that position and left my job in London, to take care of my father, who was himself fighting dementia. Those years have shaped me greatly both personally and professionally and, as September coincides with my last month at the Deloitte Centre for Health Solutions, I am delighted to use this blog to provide my reflections on the challenges presented by Alzheimer’s disease and to consider what more needs to be done to expedite progress in identifying treatments and ultimately a cure.

Continue reading

Posted on 25/09/2020 | 0 Comments

World Patient Safety Day: Speak up for health worker safety

By Samrina Bhatti, MRPharmS, PGDipGPP, Manager, and Karen Taylor, Director, Deloitte Centre for Health Solutions

Covid-orange

There is a universally accepted mantra in healthcare that no one should be harmed as a result of the treatment and care they receive. In May 2019, the seventy-second World Health Assembly adopted a resolution, ‘Global action on patient safety’ and endorsed the establishment of World Patient Safety Day (WPSD), to be observed annually on 17 September. The origin of WPSD is based on the fundamental principle of medicine – ‘First, do no harm’. Today, the global COVID-19 pandemic has highlighted the huge challenges facing health workers, including the heightened risks to their physical and mental health, and associated risk of patient harm. The WHO has therefore selected as the theme for the second WPSD, ‘Health Worker Safety: A Priority for Patient Safety, under the slogan ‘Safe health workers, Safe patients’; and a call to action, ‘Speak up for health worker safety!’.1 This week’s blog celebrates WPSD by exploring how the safety of health workers, is a priority for patient safety.

Continue reading

Posted on 18/09/2020 | 0 Comments

Digital transformation: Shaping the future of European healthcare

By Dr Francesca Properzi, PhD, Research Manager, and Krissie Ferris, Research Analyst, Centre for Health Solutions

Purple-brain

This week we launched our report Digital transformation: Shaping the future of European healthcare, our third report in our Shaping the future of health series, focused on the impact of digitalisation on the healthcare sector. While our 2019 report focused on the state of digitalisation in the UK healthcare system, this report extends our research across Europe with the aim of understanding the challenges faced by different countries, as well as the learning opportunities for both the public and private sector to improve ways of working, access to services and deliver a more effective patient and clinician experience.

Continue reading

Posted on 11/09/2020 | 0 Comments

Boosting COVID-19 vaccination rates for the hesitant

By Sarah Thomas, managing director, Deloitte Center for Health Solutions, Deloitte Services LP, and Greg Szwartz, managing director, Life Sciences data science practice lead, Deloitte Consulting LLP

Covid

This week we are sharing a blog written by our US colleagues, Sarah Thomas, the managing director of Deloitte’s US Center for Health Solutions, and Greg Szwartz, who leads the life sciences data science practice for Deloitte Consulting LLP. The focus of their blog is on ‘vaccine hesitancy’ and the finding from surveys that show that 25 to 50 per cent of Americans have said they would be hesitant to get a COVID-19 vaccination due to concerns about safety and the unprecedented speed of development. In the UK, a survey by Ipsos MORI and King’s College London found that 53 per cent of respondents said they would certainly or very likely get a vaccine against COVID-19, and 16 per cent that they are unlikely to, or definitely will not, get the vaccine.1 We believe that the strategies and tactics identified in the US blog to help improve understanding of behaviours and increase uptake of inoculations are relevant to the UK and indeed to most countries.

Continue reading

Posted on 04/09/2020 | 0 Comments

COVID-19 vaccines: a closer look at the front runners

By Maria João Cruz, PhD, Research Analyst, Centre for Health Solutions

Covid-yellow

In early May, we published a blog about the race for a COVID-19 vaccine.1 At the time, biotech and biopharma companies together with research organisations and academia had commenced the development of some 110 potential vaccines against SARS-CoV-2. Notable features of the race include the unprecedented acceleration in the pace of R&D and the significant scale of collaboration and cooperation between stakeholders across multiple geographies.2 By the end of August, there are 203 vaccine candidates under development. Six have already reached Phase III or II/III clinical trials, the last stage of clinical development before vaccines can obtain regulatory approval (see Figure 1).3,4 This was achieved in only few months, rather than the years it would normally take.5 Importantly, the COVID-19 vaccine developers are using a variety of technologies and techniques, ranging from the tried and tested to completely novel approaches. This blog explores the different approaches being used for obtaining an approved and licenced vaccine.

Continue reading

Posted on 28/08/2020 | 0 Comments

COVID-19 impact: rethinking how to plan for and run clinical trials

By Maria João Cruz, PhD, Research Analyst, Centre for Health Solutions, and Alex Grisman, Director, Deloitte

Corona-purple

Clinical trials are vital to find out whether a new medicine (or medical device) is safe, effective and better than existing treatments. Essentially, clinical trials serve to accumulate sufficient, robust evidence to assure regulators of the patient benefits from a new medical intervention. The COVID-19 pandemic has overwhelmed medical infrastructures and had a significant disruptive effect on the current clinical trial landscape. A number of our previous blogs have examined the response of biopharma companies in pivoting their research activities to try and develop COVID-19 treatments and vaccines.1,2 This week we take a look at the challenges COVID-19 is presenting to the operation of other clinical trials, including site and participant selection recruitment and retention, and the strategies that biopharma is adopting to mitigate these challenges.

Continue reading

Posted on 07/08/2020 | 0 Comments

Why I am inspired by the life sciences sector

By Mike DeLone, US life sciences leader, Deloitte LLP

Blog

I am particularly pleased this week to share with you a blog by Mike DeLone, the national sector leader for Deloitte’s US Life Sciences practice. Mike’s clear articulation of why he is feeling inspired by what he is seeing in the life sciences sector, resonated strongly with me, and I hope will resonate with those reading this blog.

Continue reading

Posted on 31/07/2020 | 0 Comments

Coalitions and collaborations are driving COVID-19 tests, treatments, and vaccines

By Greg Reh, Deloitte Global 's Life Sciences & Health Care practice

Blog

This week we are delighted to share with you a blog written by Greg Reh who leads the life sciences practice for Deloitte Global. The focus is on partnerships and collaborations which have been a feature of the industry for a number of years — particularly in terms of preventing infections and communicative diseases in underserved parts of the world. However, the COVID-19 pandemic has elevated the importance and viability of collaborations, both inside and outside of the life sciences sector, and has accelerated activity, including increasing dialogue and commitment among key industry stakeholders.

Continue reading

Posted on 24/07/2020 | 0 Comments

How face masks have become the new must-have accessory?

By Karen Taylor, Director, Centre for Health Solutions

Covid-teal

Since the outset of the COVID-19 pandemic debate has been growing about the benefits or otherwise of the general public wearing face masks to help control the spread of the virus. While arguments exist on both sides of the debate, history and culture has played a crucial role in polarising opinions. Nevertheless, all countries have accepted the need for mitigation strategies and importantly, the views of public health advisors and most governments have now converged in favour of wearing masks. While growing numbers of people across the world have begun to wear face masks in public, confusion still remains as to the merits or otherwise of wearing a mask. This week’s blog discusses of the supporting evidence for face masks and, why they have become the new ‘must have’ accessory.

Continue reading

Posted on 17/07/2020 | 0 Comments

Why COVID-19 risks undermining initiatives to reduce the global threat of antimicrobial resistance

By Samrina Bhatti, MRPharmS, PGDipGPP, Manager, Centre for Health Solutions

Covid-red

The growth of antimicrobial resistance (AMR) is widely acknowledged as an urgent public health challenge, causing at least 700,000 deaths globally every year.1 AMR also presents serious financial threats in healthcare costs and productivity losses.2 Although COVID-19 is caused by the SARS-CoV-2 virus, a growing body of international evidence shows that the global threat of AMR is worsening due to the fact that many patients with COVID-19 symptoms are being prescribed antibiotics partly due to uncertainty about the pathology of the infection; and as a precaution in preventing and treating secondary bacterial infections.3

Continue reading

Posted on 10/07/2020 | 0 Comments

Why improving the immune health of vulnerable populations would help reduce the impact of COVID-19

By Francesca Properzi, PhD, Research Manager, Deloitte Centre for Health Solutions

Covid-purple

The COVID-19 pandemic continues to have serious and far reaching consequences for the health and wealth of our population. As countries begin to move into the recovery phase, there is an urgent need to learn the lessons from local, national and international responses. A critical feature of the past four months has been an explosion in the scientific data and literature exploring how and why the pandemic has evolved and what impact is it having. This data suggest the virus is highly discriminatory and that in addition to the underlying health and age of individuals, deprivation and population density are crucial causes of higher mortality rates. What is currently less evident are insights on what we could have done to be better prepared and how we can be better prepared next time? This week’s blog provides ‘my take’ on how improving the immune health of vulnerable populations has a pivotal role to play.

Continue reading

Posted on 03/07/2020 | 0 Comments